Latest:
FDA Approval Insights: Vorasidenib in IDH1/2+ Grade 2 Astrocytoma and Oligodendroglioma
Dr Taylor discusses the significance of the FDA approval of vorasidenib for patients with IDH-positive grade 2 astrocytoma or oligodendroglioma.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Rushil V. Patel, MD
Latest:
Developing Culturally Concordant Palliative Care for Hindu Patients and Families
Sometimes, clinicians do not acknowledge how patients' values and beliefs influence how they ascribe meaning to their illness, how they prefer to receive information, and how they make decisions until the end-of-life stage, leading to misunderstandings between clinicians and patients.
Shailee S. Shah, MD
Shailee S. Shah, MD, is a clinical assistant professor of Neurology (MS/Neuroimmunology) at Northwestern University Feinberg School of Medicine.
Latest:
Accurate Symptom Identification and Guidelines Support LEMS Screening and Diagnosis: With Jacob Sands, MD; and Shailee Shah, MD
Drs Sands and Shah discuss LEMS symptom identification and what guidelines currently note as best practices for the diagnosis of this disease.
Brian P. Mulherin, MD
Brian P. Mulherin, MD, is the medical director of the American Oncology Network and a hematologist oncologist at Hematology Oncology of Indiana in Indianapolis.
Latest:
Dr Mulherin on Using AI to Address NGS Testing Barriers in Oncology Practice
Brian P. Mulherin, MD, discusses using AI tools to improve the implementation of NGS in community oncology practice.